These data highlight the ‘push and pull’ relationship that LRRC15+ CAFs have with universal fibroblasts to establish a tumour fibroblast setpoint that ultimately suppresses anti-tumour T cell immunity and the effectiveness of ICB therapy. The gene discussed is LRRC15; the disease is neoplasm.